Empowering Patients to Improve Safety in Polymedication

Launched by LEIDEN UNIVERSITY MEDICAL CENTER · May 1, 2025

Keywords

ClinConnect Summary

This clinical trial, called the SafePolyMed project, is studying how a new online tool can help patients who are taking multiple medications, known as polypharmacy. Polypharmacy typically involves using five or more drugs, which can lead to safety concerns due to possible harmful interactions between these medications. The goal of the trial is to see if this tool can empower patients by providing personalized information about their medications and any potential risks, ultimately improving their safety and understanding of their health.

To participate in this study, individuals must be at least 18 years old and currently taking five or more medications. They will use the online medication management center for 12 weeks and complete questionnaires to share their experiences. Participants will also provide a small blood sample for genetic testing, which can help tailor medication choices to their unique needs. This trial is being conducted across four European countries, and while there are minimal risks involved, participants will continue to receive their normal medical care throughout the study. The trial aims to help patients better manage their health and medication safety.

Gender

ALL

Eligibility criteria

• In order to be eligible to participate in this study, a subject must meet all of the following crite-ria:
• • Polypharmacy defined as the use of 5 or more drugs
• • Start usage of at least one index drug according to the list in table 3.
• • Subject must be ≥ 18 years old
• • Subject is able and willing to take part and be followed-up for at least 12 weeks
• • Subject is able to donate blood or saliva
• • Subject has signed informed consent
• A potential subject who meets any of the following criteria will be excluded from participation in this study:
• • Pregnancy or lactating
• • Life expectancy estimated to be less than three months by treating clinical team
• • Unable to consent to the study
• • Unwilling to take part
• • Subject has no fixed address
• • Subject has previously been genotyped for PGx genes
• • Subject has no current general practitioner
• • Subject is, in the opinion of the Investigator, not suitable to participate in the study
• • Estimated glomerular filtration rate (MDRD) of less than 15 ml/min per 1,73m2
• • Patients with advanced liver failure (stage Child-Pugh C)